Clinical Trial Update: Common Safety Follow-up Trial of Tecemotide (L-BLP25) [NA]

View source ↗

Summary

The common safety follow-up trial of Tecemotide (L-BLP25) was terminated, with results posted on 2016-10-06.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma
• Non-small Cell Lung Cancer

Drugs mentioned

• Tecemotide (L-BLP25)

Snippet

Sponsor: Merck KGaA, Darmstadt, Germany | Conditions: Non-Small Cell Lung Cancer, Multiple Myeloma | NA | Status: TERMINATED | Results posted: 2016-10-06